Matteo Fornai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2783716/publications.pdf

Version: 2024-02-01

141 papers	4,803 citations	81839 39 h-index	133188 59 g-index
141 all docs	141 docs citations	141 times ranked	6595 citing authors

#	Article	IF	Citations
1	Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases?. Acta Neuropathologica, 2018, 136, 345-361.	3.9	167
2	Intestinal Fungal Dysbiosis Is Associated With Visceral Hypersensitivity in Patients With Irritable Bowel Syndrome and Rats. Gastroenterology, 2017, 153, 1026-1039.	0.6	160
3	Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation. Frontiers in Immunology, 2017, 8, 36.	2.2	151
4	Adenosine and inflammation: what's new on the horizon?. Drug Discovery Today, 2014, 19, 1051-1068.	3.2	139
5	Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease. Journal of Medicinal Chemistry, 2017, 60, 3656-3671.	2.9	131
6	Adenosine signaling and the immune system: When a lot could be too much. Immunology Letters, 2019, 205, 9-15.	1.1	130
7	Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders. Current Drug Targets, 2012, 13, 842-862.	1.0	128
8	Regulation of enteric functions by adenosine: Pathophysiological and pharmacological implications. , 2008, 120, 233-253.		103
9	Endothelial Dysfunction in Small Arteries of Essential Hypertensive Patients. Hypertension, 2013, 62, 337-344.	1.3	97
10	Inhibition of Adenosine Deaminase Attenuates Inflammation in Experimental Colitis. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 435-442.	1.3	96
11	Cyclooxygenase-2 Inhibition Improves Vascular Endothelial Dysfunction in a Rat Model of Endotoxic Shock: Role of Inducible Nitric-Oxide Synthase and Oxidative Stress. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 945-953.	1.3	92
12	Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: A review. Clinical Therapeutics, 2009, 31, 1426-1453.	1.1	92
13	Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications?. Progress in Neurobiology, 2020, 191, 101806.	2.8	87
14	Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. Journal of Neuroinflammation, 2016, 13, 146.	3.1	77
15	Altered prejunctional modulation of intestinal cholinergic and noradrenergic pathways by Î± 2 -adrenoceptors in the presence of experimental colitis. British Journal of Pharmacology, 2003, 139, 309-320.	2.7	74
16	NKG2A and COVID-19: another brick in the wall. Cellular and Molecular Immunology, 2020, 17, 672-674.	4.8	72
17	Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases. International Journal of Molecular Sciences, 2019, 20, 2876.	1.8	67
18	Cyclooxygenase-1 Is Involved in Endothelial Dysfunction of Mesenteric Small Arteries From Angiotensin IIâ€“Infused Mice. Hypertension, 2007, 49, 679-686.	1.3	66

#	Article	IF	Citations
19	Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. Drug Discovery Today, 2017, 22, 1686-1696.	3.2	66
20	Atorvastatin Prevents Endothelial Dysfunction in Mesenteric Arteries From Spontaneously Hypertensive Rats. Hypertension, 2009, 53, 1008-1016.	1.3	62
21	Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. World Journal of Gastroenterology, 2005, 11, 4052.	1.4	61
22	The role of purinergic pathways in the pathophysiology of gut diseases: Pharmacological modulation and potential therapeutic applications. , 2013, 139, 157-188.		60
23	Drug-Induced Taste and Smell Alterations. Drug Safety, 2011, 34, 849-859.	1.4	58
24	Mechanisms of gastroprotection by lansoprazole pretreatment against experimentally induced injury in rats: role of mucosal oxidative damage and sulfhydryl compounds. Toxicology and Applied Pharmacology, 2004, 195, 62-72.	1.3	57
25	Pharmacological modulation of adenosine system: Novel options for treatment of inflammatory bowel diseases. Inflammatory Bowel Diseases, 2008, 14, 566-574.	0.9	57
26	Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence. Parkinsonism and Related Disorders, 2015, 21, 1407-1414.	1.1	56
27	Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy. Translational Neurodegeneration, 2019, 8, 5.	3.6	54
28	Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug. Clinical Drug Investigation, 2002, 22, 799-818.	1.1	52
29	Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut, 2005, 54, 608-616.	6.1	52
30	Neuropsychiatric Adverse Events Associated with Statins: Epidemiology, Pathophysiology, Prevention and Management. CNS Drugs, 2014, 28, 249-272.	2.7	52
31	Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy. Oncologist, 2010, 15, 1214-1219.	1.9	51
32	Enteric Dysfunctions in Experimental Parkinsons Disease: Alterations of Excitatory Cholinergic Neurotransmission Regulating Colonic Motility in Rats. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 233-243.	1.3	49
33	The Blockade of Adenosine Deaminase Ameliorates Chronic Experimental Colitis through the Recruitment of Adenosine A_{2A}and A₃Receptors. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 434-442.	1.3	47
34	The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity. PLoS ONE, 2018, 13, e0195502.	1.1	47
35	Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity. Frontiers in Pharmacology, 2018, 9, 1094.	1.6	46
36	Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. Naunyn-Schmiedeberg's Archives of Pharmacology, 2005, 372, 79-87.	1.4	45

#	Article	IF	Citations
37	Exploiting the Pyrazolo[3,4-d]pyrimidin-4-one Ring System as a Useful Template To Obtain Potent Adenosine Deaminase Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 1681-1692.	2.9	44
38	NSAID-Induced Enteropathy: Are the Currently Available Selective COX-2 Inhibitors All the Same?. Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 86-95.	1.3	44
39	Differential recruitment of high affinity A1 and A2A adenosine receptors in the control of colonic neuromuscular function in experimental colitis. European Journal of Pharmacology, 2011, 650, 639-649.	1.7	41
40	Involvement of the P2X7 Purinergic Receptor in Colonic Motor Dysfunction Associated with Bowel Inflammation in Rats. PLoS ONE, 2014, 9, e116253.	1.1	41
41	Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models. Neurogastroenterology and Motility, 2016, 28, 1781-1791.	1.6	41
42	The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders. Expert Opinion on Therapeutic Targets, 2016, 20, 179-191.	1.5	41
43	Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. Alimentary Pharmacology and Therapeutics, 2020, 52, 284-291.	1.9	41
44	Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy. Pharmacological Research, 2009, 59, 90-100.	3.1	40
45	Dietary flavonoids as a potential intervention to improve redox balance in obesity and related co-morbidities: a review. Nutrition Research Reviews, 2018, 31, 239-247.	2.1	40
46	A2a receptors mediate inhibitory effects of adenosine on colonic motility in the presence of experimental colitis. Inflammatory Bowel Diseases, 2006, 12, 117-122.	0.9	39
47	Influence of the Serotonin Transporter 5HTTLPR Polymorphism on Symptom Severity in Irritable Bowel Syndrome. PLoS ONE, 2013, 8, e54831.	1.1	37
48	Enteric Î±-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinsonâ€™s disease before brain pathology. Npj Parkinson's Disease, 2022, 8, 9.	2.5	36
49	Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention. Frontiers in Pharmacology, 2018, 9, 1340.	1.6	35
50	Enteric Glia at the Crossroads between Intestinal Immune System and Epithelial Barrier: Implications for Parkinson Disease. International Journal of Molecular Sciences, 2020, 21, 9199.	1.8	35
51	Differential Role of Cyclooxygenase 1 and 2 Isoforms in the Modulation of Colonic Neuromuscular Function in Experimental Inflammation. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 938-945.	1.3	34
52	Use of Selective Serotonin Reuptake Inhibitors during Pregnancy and Risk of Major and Cardiovascular Malformations: An Update. Postgraduate Medicine, 2010, 122, 49-65.	0.9	34
53	Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: Characterization of molecular mechanisms. Pharmacological Research, 2011, 63, 59-67.	3.1	34
54	Inducible Nitric Oxide Synthase Is Involved in Endothelial Dysfunction of Mesenteric Small Arteries from Hypothyroid Rats. Endocrinology, 2009, 150, 1033-1042.	1.4	33

#	Article	IF	Citations
55	A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation. Frontiers in Pharmacology, 2018, 9, 1405.	1.6	33
56	Allopurinol adherence among patients with gout: an Italian general practice database study. International Journal of Clinical Practice, 2015, 69, 757-765.	0.8	31
57	Colonic dysmotility associated with highâ€fat dietâ€induced obesity: Role of enteric glia. FASEB Journal, 2020, 34, 5512-5524.	0.2	31
58	Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. Pharmacological Research, 2016, 104, 186-196.	3.1	30
59	Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors. Purinergic Signalling, 2017, 13, 497-510.	1.1	30
60	Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. British Journal of Clinical Pharmacology, 2020, 86, 1296-1305.	1.1	30
61	Control of enteric neuromuscular functions by purinergic A₃ receptors in normal rat distal colon and experimental bowel inflammation. British Journal of Pharmacology, 2010, 161, 856-871.	2.7	29
62	An integrated assessment of histopathological changes of the enteric neuromuscular compartment in experimental colitis. Journal of Cellular and Molecular Medicine, 2015, 19, 485-500.	1.6	29
63	Resistance artery mechanics and composition in angiotensin II-infused mice: effects of cyclooxygenase-1 inhibition. European Heart Journal, 2012, 33, 2225-2234.	1.0	28
64	Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration. Neurobiology of Disease, 2020, 139, 104821.	2.1	28
65	NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications. Medicinal Research Reviews, 2021, 41, 1890-1926.	5.0	28
66	Intestinal epithelial barrier and neuromuscular compartment in health and disease. World Journal of Gastroenterology, 2020, 26, 1564-1597.	1.4	28
67	Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions. , 2010, 125, 62-78.		27
68	Adverse reactions to oncologic drugs: spontaneous reporting and signal detection. Expert Review of Clinical Pharmacology, 2015, 8, 61-75.	1.3	27
69	Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity. International Journal of Obesity, 2019, 43, 331-343.	1.6	27
70	Clinical evaluation of piroxicam-FDDF and azithromycin in the prevention of complications associated with impacted lower third molar extraction. Pharmacological Research, 2005, 52, 485-490.	3.1	26
71	Characterization of mechanisms underlying the effects of esomeprazole on the impairment of gastric ulcer healing with addition of NSAID treatment. Digestive and Liver Disease, 2009, 41, 395-405.	0.4	26
72	Role of the <scp>A_{2B}</scp> receptorâ€“adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rats. British Journal of Pharmacology, 2014, 171, 1314-1329.	2.7	26

#	Article	IF	Citations
73	Constitutive expression of cyclooxygenase-2 in the neuromuscular compartment of normal human colon. Neurogastroenterology and Motility, 2006, 18, 654-662.	1.6	25
74	Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects. Drug Safety, 2016, 39, 903-924.	1.4	25
75	A₁ and A_{2a} receptors mediate inhibitory effects of adenosine on the motor activity of human colon. Neurogastroenterology and Motility, 2009, 21, 451-466.	1.6	24
76	P2X4 receptors, immunity, and sepsis. Current Opinion in Pharmacology, 2019, 47, 65-74.	1.7	24
77	Prodromal Intestinal Events in Alzheimerâ€™s Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition. International Journal of Molecular Sciences, 2020, 21, 3523.	1.8	24
78	Clinical Efficacy of Esomeprazole in the Prevention and Healing of Gastrointestinal Toxicity Associated with NSAIDs in Elderly Patients. Drugs and Aging, 2008, 25, 197-208.	1.3	23
79	Deepening the Mechanisms of Visceral Pain Persistence: An Evaluation of the Gut-Spinal Cord Relationship. Cells, 2020, 9, 1772.	1.8	22
80	Glial A2B Adenosine Receptors Modulate Abnormal Tachykininergic Responses and Prevent Enteric Inflammation Associated with High Fat Diet-Induced Obesity. Cells, 2020, 9, 1245.	1.8	20
81	Anti-inflammatory effect of a novel locally acting A2A receptor agonist in a rat model of oxazolone-induced colitis. Purinergic Signalling, 2018, 14, 27-36.	1.1	19
82	Pathophysiology of Gastric Ulcer Development and Healing: Molecular Mechanisms and Novel Therapeutic Options. , 0, , .		18
83	Rosuvastatin prevents angiotensin <scp>II</scp>â€induced vascular changes by inhibition of <scp>NAD</scp>(<scp>P</scp>)<scp>H</scp> oxidase and <scp>COX</scp>â€1. British Journal of Pharmacology, 2013, 169, 554-566.	2.7	18
84	High Levels of Î²-Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-16.	1.9	18
85	Adenosine Signaling in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1270, 145-167.	0.8	18
86	Differential Impact of Weight Loss and Glycemic Control on Inflammasome Signaling. Obesity, 2020, 28, 609-615.	1.5	17
87	Derivatives of Benzimidazolâ€2â€ylquinoline and Benzimidazolâ€2â€ylisoquinoline as Selective A₁ Adenosine Receptor Antagonists with Stimulant Activity on Human Colon Motility. ChemMedChem, 2011, 6, 1909-1918.	1.6	16
88	Adenosine pathway and cancer: where do we go from here?. Expert Opinion on Therapeutic Targets, 2014, 18, 973-977.	1.5	16
89	Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy. Nutrition, 2020, 70, 110583.	1.1	16
90	The Adenosine System at the Crossroads of Intestinal Inflammation and Neoplasia. International Journal of Molecular Sciences, 2020, 21, 5089.	1.8	16

#	Article	IF	Citations
91	Ectopic Lymphoid Organs and Immune-Mediated Diseases: Molecular Basis for Pharmacological Approaches. Trends in Molecular Medicine, 2020, 26, 1021-1033.	3.5	16
92	Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. Drug Safety, 2015, 38, 869-888.	1.4	15
93	Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. Neuropharmacology, 2017, 123, 22-33.	2.0	15
94	Neuronal regulation of intestinal immune functions in health and disease. Neurogastroenterology and Motility, 2018, 30, e13406.	1.6	15
95	Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases. Frontiers in Pharmacology, 2018, 9, 212.	1.6	15
96	Nonsteroidal Anti-Inflammatory Drug-Activated Gene-1 Plays a Role in the Impairing Effects of Cyclooxygenase Inhibitors on Gastric Ulcer Healing. Journal of Pharmacology and Experimental Therapeutics, 2012, 342, 140-149.	1.3	14
97	Cholecystokinin CCK2 receptors mediate the peptide's inhibitory actions on the contractile activity of human distal colon via the nitric oxide pathway. British Journal of Pharmacology, 2007, 151, 1246-1253.	2.7	13
98	Genetics and pharmacogenetics of aminergic transmitter pathways in functional gastrointestinal disorders. Pharmacogenomics, 2015, 16, 523-539.	0.6	13
99	The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis. Cells, 2020, 9, 1509.	1.8	13
100	Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimerâ€™s Disease. Frontiers in Pharmacology, 2021, 12, 748021.	1.6	13
101	Telogen Effluvium following Bivalent Human Papillomavirus Vaccine Administration: A Report of Two Cases. Dermatology, 2012, 224, 212-214.	0.9	12
102	Safety of MF-59 adjuvanted vaccine for pandemic influenza: Results of the vaccination campaign in an Italian health district. Vaccine, 2011, 29, 3443-3448.	1.7	11
103	Anti-inflammatory Effects of Novel P2X4 Receptor Antagonists, NC-2600 and NP-1815-PX, in a Murine Model of Colitis. Inflammation, 2022, 45, 1829-1847.	1.7	11
104	A holistic view of adenosine in the control of intestinal neuromuscular functions: the enteric â€˜purinomeâ€™ concept. British Journal of Pharmacology, 2011, 164, 1577-1579.	2.7	10
105	Role of cyclooxygenase isoforms in the altered excitatory motor pathways of human colon with diverticular disease. British Journal of Pharmacology, 2014, 171, 3728-3740.	2.7	10
106	Effects of a bicarbonate-alkaline mineral water on digestive motility in experimental models of functional and inflammatory gastrointestinal disorders. Methods and Findings in Experimental and Clinical Pharmacology, 2008, 30, 261.	0.8	10
107	Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases. Minerva Gastroenterologica E Dietologica, 2020, 65, 298-308.	2.2	10
108	Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab. Digestive and Liver Disease, 2022, 54, 1367-1373.	0.4	10

#	Article	IF	Citations
109	CCK2 receptors mediate inhibitory effects of cholecystokinin on the motor activity of guinea-pig distal colon. European Journal of Pharmacology, 2007, 557, 212-220.	1.7	9
110	Approaches for designing and discovering purinergic drugs for gastrointestinal diseases. Expert Opinion on Drug Discovery, 2020, 15, 687-703.	2.5	9
111	NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of dietâ€induced obesity. British Journal of Pharmacology, 2021, 178, 3924-3942.	2.7	9
112	Risankizumab for the treatment of moderate to severe psoriasis. Expert Opinion on Biological Therapy, 2019, 19, 1-8.	1.4	8
113	Inflammatory Bowel Diseases: It's Time for the Adenosine System. Frontiers in Immunology, 2020, 11, 1310.	2.2	7
114	Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System?. Frontiers in Pharmacology, 2020, 11, 621955.	1.6	7
115	Cyclooxygenase-2 Induction after Oral Surgery Does Not Entirely Account for Analgesia after Selective Blockade of Cyclooxygenase 2 in the Preoperative Period. Anesthesiology, 2006, 104, 152-157.	1.3	6
116	Adenosine Regulation of the Immune System. , 2018, , 499-514.		6
117	From the intestinal mucosal barrier to the enteric neuromuscular compartment: an integrated overview on the morphological changes in Parkinsonâ€™s disease. European Journal of Histochemistry, 2021, 65, .	0.6	6
118	Effects of pantoprazole on ulcer healing delay associated with NSAID treatment. Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379, 305-313.	1.4	5
119	Transient acute liver failure complicating transurethral resection syndrome. Scandinavian Journal of Urology and Nephrology, 2010, 44, 269-272.	1.4	5
120	Preclinical Development of FA5, a Novel AMP-Activated Protein Kinase (AMPK) Activator as an Innovative Drug for the Management of Bowel Inflammation. International Journal of Molecular Sciences, 2021, 22, 6325.	1.8	5
121	Pharmacological modulation of adenosine receptor pathways and inflammatory disorders: the way towards novel therapeutics?. Expert Opinion on Investigational Drugs, 2011, 20, 717-721.	1.9	4
122	Quality of Adverse Drug Reaction (QADRA) reports: an algorithm to appraise the efficiency of spontaneous reporting systems in pharmacovigilance. Zeitschrift Fur Gesundheitswissenschaften, 2013, 21, 365-372.	0.8	4
123	Role of proteinase-activated receptors 1 and 2 in nonsteroidal anti-inflammatory drug enteropathy. Pharmacological Reports, 2020, 72, 1347-1357.	1.5	4
124	Donepezil improves vascular function in a mouse model of Alzheimerâ€™s disease. Pharmacology Research and Perspectives, 2021, 9, e00871.	1.1	4
125	Tolerability Profiles of Leukotriene Receptor Antagonists and Long-Acting Î²2-Adrenoceptor Agonists in Combination with Inhaled Corticosteroids for Treatment of Asthma: A Review. Journal of Asthma, 2007, 44, 411-422.	0.9	3
126	Tu1889 Targeting of NLRP3 Inflammasome With a Novel Selective Inhibitor as a Suitable Strategy for the Pharmacological Treatment of Bowel Inflammation. Gastroenterology, 2016, 150, S968-S969.	0.6	3

#	Article	IF	Citations
127	IMPROVED TONSILLAR DISPOSITION OF AZITHROMYCIN FOLLOWING A 3-DAY ORAL TREATMENT WITH 20 mg kgâ^'1 IN PAEDIATRIC PATIENTS. Pharmacological Research, 2002, 46, 95-100.	3.1	2
128	Editorial: IBD Managementâ€"Novel Targets and Therapeutic Perspectives. Frontiers in Pharmacology, 2020, 11, 448.	1.6	2
129	15 Altered Adenosine Signalling in the Presence of Bowel Inflammation: Role of a2B Receptors in the Control of Colonic Motility. Gastroenterology, 2012, 142, S-4.	0.6	1
130	Response to Endothelial Nitric Oxide Synthase, Cyclooxygenase-2, and Essential Hypertension: Is There an Interaction?. Hypertension, 2013, 62, e16.	1.3	1
131	Comment on â€œHigh expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinomaâ€. Tumor Biology, 2015, 36, 7397-7398.	0.8	1
132	Colonic Dysmotility Associated with High Fat Diet-Induced Obesity: Role of the Enteric Glia. Gastroenterology, 2017, 152, S180.	0.6	1
133	The role of serotonin and its pathways in gastrointestinal disorders. , 2021, , 67-94.		1
134	P709 Early measurement of serum cytokines as predictor of clinical and endoscopic outcome to vedolizumab in patients with ulcerative colitis. Journal of Crohn's and Colitis, 2019, 13, S475-S475.	0.6	0
135	Colonic dysmotility and inflammation associated with high fat diet-induced obesity: role of the enteric glia. Proceedings of the Nutrition Society, 2020, 79, .	0.4	0
136	P454 Serum oncostatin M predicts mucosal healing in Crohnâ€™s disease patients treated with infliximab. Journal of Crohn's and Colitis, 2020, 14, S406-S406.	0.6	0
137	The flavonoid compound luteolin prevents endothelial dysfunction in a mouse model of high fat diet-induced obesity. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-2-47.	0.0	0
138	FA-5, a novel AMP-activated protein kinase (AMPK) activator, as a new pharmacological tool for the management of bowel inflammation. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-5-2.	0.0	0
139	Rifaximin prevents diclofenac-induced enteropathy in rats through antibacterial and anti-inflammatory activities. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-5-28.	0.0	0
140	A comparative study on the efficacy of NLRP3 inflammasome signaling inhibitors in a pre-clinical model of bowel inflammation. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-6-29.	0.0	0
141	Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximabâ€"authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 1082-1082.	1.9	0